Your company is sponsoring a multicenter clinical trial of an inhaled insulin product in partnership with a large pharmaceutical company. Four deaths have occurred at three sites within the last month and ABC News has contacted you for comment on the deaths and your company.s product. How do you respond?
Please join BioE2E as we simulate a company.s response to this clinical crisis. Our panel of participants will take on the roles of CEO, legal counsel, regulatory and clinical representatives of a fictitious company and together formulate a response to such a crisis. Marcia Kean, CEO of Feinstein Kean Healthcare, and Jeremiah Hall, Vice President at Ogilvy PR/San Francisco, will guide the panel and the audience in the steps to appropriate crisis communications. Attendees will learn how to how to address the news media and what to say in response to such as crisis as well as how to respond to and work with pharmco partners, shareholders, clinical trial sites, regulators and employees. Attendees will also learn the six steps to crisis communications.
Networking session will follow.
Presenters:
|
Marcia Kean, CEO, Feinstein Kean Healthcare
|
|
|
|
|
|
Jeremiah Hall, Vice President, Ogilvy Public Relations Worldwide/San Francisco
|
|
|
|